influenza prevention
Vaccines · 2018–2024
4decisions
3medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| quadrivalent recombinant influenza vaccine Prevention of influenza in people aged 65 years and over. | Mar 2024 | Recommended | input received Lung Foundation Australia |
| cell-cultured quadrivalent influenza vaccine (surface antigen, inactivated) Prevention of influenza in children aged 6 months to <5 years, Aboriginal and Torres Strait Islander people aged ≥6 months to <65 years, persons aged ≥6 months… | Mar 2024 | Recommended with restriction | input received Lung Foundation Australia |
| inactivated quadrivalent influenza vaccine (split virion) Prevention of influenza caused by Influenza Virus Types A and B in children aged 6 months to <5 years, including at-risk children aged 6-35 months with medical… | Nov 2019 | Recommended | none received |
| inactivated quadrivalent influenza vaccine (split virion) Prevention of influenza caused by Influenza Virus Types A and B in persons aged 5–17 years who are at increased risk of complications from influenza,… | Nov 2018 | Recommended | none received |
Who spoke
Lung Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.